Posted on May 17, 20265/17/26
Can Direct‑to‑Employer Models Redefine Access to Obesity Care?
Posted on May 13, 20265/13/26
Views from Asembia: What Pharma Leaders Are Prioritizing Now
Posted on May 8, 20265/8/26
How MFN is Reshaping Global Drug Pricing – and How NAVLIN Insights Tracks It
Posted on May 7, 20265/7/26
How Pharma Can Scale Innovation Without Losing Executional Rigor
Posted on May 6, 20265/6/26
Predicting PICOs Under EU Joint Clinical Assessment: Is One Method Enough?
Posted on April 30, 20264/30/26
Winners Circle Podcast: How EVERSANA Built an 80/20 AI Model That Works
Posted on April 24, 20264/24/26
The Strategic Advantage: Why a Vendor-Neutral Approach is Key to PV Success
Posted on April 23, 20264/23/26
From Experimentation to Ownership: Why the Future Belongs to Companies That Own AI
Posted on April 21, 20264/21/26
A New Standard for Copay Excellence: How Pharma Can Rethink Affordability
Posted on April 10, 20264/10/26